查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1247466

2023-2030 年全球原位杂交 (ISH) 市场

Global In Situ Hybridization Market - 2023-2030
出版日期: | 出版商: DataM Intelligence | 英文 195 Pages | 商品交期: 约2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

市场概览

原位杂交的全球市场预计到 2022 年将达到 97.4 亿美元，到 2030 年将达到 150.8746 亿美元。 在预测期内（2023 年至 2030 年），该市场的复合年增长率为 11.9%。

原位杂交 (ISH) 使用标记的互补 DNA、RNA 或修饰的核酸链（即探针）来识别组织或组织的一部分或部分中的特定 DNA 或 RNA 序列。当足够小时，它定位于整个组织（例如，植物种子、果蝇胚胎）、细胞和循环肿瘤细胞 (CTC) 内。 通常将蛋白质定位到组织切片的免疫组织化学是不同的。

市场动态

癌症患者人数上升

吸烟和不良的饮食习惯会增加癌症的发病率。 这是 ISH 市场的主要增长因素。 例如，世界卫生组织报告说，癌症将成为 2020 年全球死亡的主要原因，约有 1000 万人死亡，即每 6 人中就有 1 人死亡。 乳腺癌、肺癌、结肠癌、直肠癌和前列腺癌是最常见的癌症类型。 烟草使用、高度肥胖、饮酒、饮食中水果和蔬菜含量低以及缺乏锻炼约占癌症死亡人数的三分之一。

在低收入和中等收入国家，人乳头瘤病毒 (HPV) 和肝炎等致癌感染被认为占癌症病例的 30%。 因此，原位杂交的需求在预计期间将会增加。

缺乏训练有素的人力阻碍了市场。

为了执行基于 ISH 的测试，必须熟悉染色体和基因的分子规格。 从手动转向自动化的阻力也阻碍了行业的发展。 对于许多供应商来说，从手动和过时的流程迁移到基于 IT 的流程即使不是不可能，也是很困难的。 出于这个原因，基于 ISH 的诊断的广泛使用受到合格、受过教育和技术熟练的实验室人员短缺的限制，特别是在发展中国家。

内容

第 1 章研究方法和范围

  • 调查方法
  • 调查目的和范围

第 2 章定义和概述

第 3 章执行摘要

  • 片段类型
  • 按应用程序摘录
  • 最终用户的片段
  • 区域摘要

第 4 章动力学

  • 影响因子
    • 司机
      • 癌症发病率增加
      • 了解伴随诊断
    • 约束因素
      • 缺乏训练有素的人力阻碍了市场
    • 机会
    • 影响分析

第五章行业分析

  • 波特的五力分析
  • 供应链分析
  • 价格分析
  • 监管分析
  • 未满足的需求
  • 管道解析

第 6 章 COVID-19 分析

  • COVID-19 分析
    • 在 COVID-19 情景之前
    • 当前的 COVID-19 情景
    • COVID-19 后或未来情景
  • COVID-19 期间的价格动态
  • 供需范围
  • 大流行期间与市场相关的政府举措
  • 製造商的战略举措
  • 结论

第 7 章副产品

  • 消耗品
  • 仪器
  • 软件

第八章技术

  • 鱼
    • DNA鱼
    • RNA 鱼
    • 巴拿马鱼
  • 师叔

第 9 章按应用

  • 癌症诊断剂
  • 细胞学
  • 传染病诊断试剂
  • 神经科学
  • 免疫学

第 10 章最终用户

  • 医院/诊断药物研究所
  • 学术和研究机构等
  • 製药和生物技术公司
  • 委託研究机构

第11章按地区

  • 北美
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 意大利
    • 俄罗斯
    • 其他欧洲
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他南美洲
  • 亚太地区
    • 中国
    • 印度
    • 日本
    • 澳大利亚
    • 其他亚太地区
  • 中东和非洲

第12章竞争格局

  • 竞争场景
  • 市场分析/份额分析
  • 併购分析

第13章公司简介

  • 雅培实验室
    • 公司简介
    • 产品组合和说明
    • 财务摘要
    • 主要发展
  • F. Hoffmann-La Roche Ag.
  • Becton, Dickinson And Company
  • Agilent Technologies, Inc.
  • Thermo Fisher Scientific
  • Bio-Rad Laboratories, Inc.
  • Bio-Techne Corporation
  • Creative Bioarray
  • Biocat Gmbh
  • Zytovision.

第14章 附录

简介目录
Product Code: BT3183

Market Overview

The global In Situ Hybridization market reached US$ 9700.40 million in 2022 and is projected to witness lucrative growth by reaching up to US$ 15087.46 million by 2030. The market is growing at a CAGR of 11.9% during the forecast period (2023-2030).

In situ hybridization (ISH) uses a labeled complementary DNA, RNA, or modified nucleic acid strand (i.e., probe) to localize a particular DNA or RNA sequence in a portion or section of tissue, or if the tissue is small enough, in the entire tissue (e.g., plant seeds, Drosophila embryos), in cells, and in circulating tumor cells (CTCs). Immunohistochemistry, which often localizes proteins in tissue slices, is different from this.

Market Dynamics

The Increasing incidence of Cancer cases

Smoking and poor eating habits are to responsible for the increase in cancer occurrences. That is a significant growth factor for the ISH market. For instance, the WHO reports that cancer will be the top cause of mortality globally in 2020, accounting for around 10 million deaths, or roughly one in every six. Breast, lung, colon, rectum, and prostate cancers are the most prevalent types of cancer. The use of tobacco, having a high body mass index, drinking alcohol, eating few fruits and vegetables, and not exercising account for about one-third of cancer-related fatalities.

In low- and lower-middle-income nations, cancer-causing infections including the human papillomavirus (HPV) and hepatitis are thought to be the cause of 30% of cancer cases. And as a result, in-situ hybridization demand is increasing during the anticipated period.

The Lack of trained personnel will hamper the market.

To carry out an ISH-based test, one needs to be aware of the molecular specifics of a chromosome or gene. Resistance to the transition from manual to automated procedures is another barrier to the industry's growth. Too many suppliers, making the transfer from manual or antiquated processes to IT-based ones is challenging, if not impossible. Because of this, the broad use of ISH-based diagnosis is limited, particularly in developing countries, by a lack of qualified, educated, and technically adept laboratory personnel.

Segment Analysis

The global In Situ Hybridization market is segmented based on product, technology, application, end user,and region.

On basis of the technology, FISH isexpected to hold the largest share

The FISH segment is expected to hold the largest share in the In Situ Hybridization market owing to the increasing number oforthopedic surgeries across the globe. For instance, a chromosome from a person is attached to a glass slide using the Fluorescence In Situ Hybridization (FISH) laboratory procedure, which exposes the chromosome to a probe made of purified DNA that has been fluorescently dyed. It is used to diagnose cancer, chromosomal abnormalities, gene mapping, and genetic illnesses. Growing genetic problems, chronic diseases, and rising demand for effective diagnostic methods are factors in the expansion of the FISH segment. And when more products are released by different market players, the market expands as a result of the rising demand for FISH methods.

For instance, in May 2021, as a part of its newly launched Vizgen release program, Vizgen launched its publicly accessible data collection. The precise location of transcripts from 483 genes can be found in the open-source spatial genomics dataset known as the Vizgen multiplexed error resilient fluorescence in situ hybridization mouse brain receptor map. Therefore, the above-mentioned factors help the FISH segment to dominate the market.

Geographical Penetration

Rising higher rates of infectious diseases, genetic abnormalities drives the region

North America'sIn Situ Hybridization market is anticipated to grow in the forecast period owing to increasing product launches by the key players in the region. For instance, because to the region's higher rates of infectious diseases, genetic abnormalities, and cancer, North America is anticipated to hold the majority of the market share for in situ hybridization. The market is also anticipated to increase as a result of increasing research and development efforts, the existence of major industry competitors, and regular product debuts. For instance, estimated numbers of new cancer cases and fatalities in 2022, according of the American Cancer Society (In 2022, there will be an estimated 1.9 million new cancer cases diagnosed and 609,360 cancer deaths in the United States.). The 2022 year special section examines the prevalence of cancer risk factors and screening among American Indian and Alaska Native (AIAN) people.

Competitive Landscape

The major global players in the market include Abbott Laboratories, F. Hoffmann-La Roche Ag, Becton, Dickinson And Company, Agilent Technologies, Inc, Thermo Fisher Scientific, Bio-Rad Laboratories, Inc, Bio-Techne Corporation, Creative Bioarray, Biocat Gmbh, Zytovision.

COVID-19 Impact Analysis

By Product

  • Consumables
  • Instruments
  • Software

By Technology

  • FISH
    • DNA FISH
    • RNA FISH
    • PNA FISH
  • CISH

By Application

  • Cancer Diagnostics
  • Cytology
  • Infectious Disease Diagnostics
  • Neuroscience
  • Immunology

By End User

  • Hospitals & Diagnostic Laboratories
  • Academic & Research Institutes
  • Pharmaceutical & Biotechnology Companies
  • Contract research organizations

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • France
    • Italy
    • Russia
    • Rest of Europe
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • Rest of Asia-Pacific
  • Middle East and Africa

Key Developments

  • In April 6, 2021, A strategic business relationship between Applied Spectral Imaging (ASI) and KromaTiD, Inc. has been announced. Under this partnership, ASI will have the exclusive worldwide rights to offer Pinpoint FISH (PPF) probes and test services developed by KromaTiD.
  • In March 10, 2020, an Improved FISH Probe is Introduced by Creative Bioarray to Identify 2019 New Coronavirus. Viral particles in infected cells can be recognized using in site hybridization (ISH), which also offers precise molecular identification and visualization of infected cell types and regions.
  • On May 26, 2020, The CE-IVD designated RNAscope In Situ Hybridization Detection Kit for automation on the BOND-III platform has been made available in Europe by Leica Biosystems and Bio-Techne. Leica's platform and Bio-RNAscope Techne will give pathologists access to the top applications to help their diagnostics labs.

Why Purchase the Report?

  • To visualize the global In Situ Hybridization- market segmentation based on product, technology, application, end-user, and region, as well as understand key commercial assets and players.
  • Identify commercial opportunities by analyzing trends and co-development.
  • Excel data sheet with numerous data points of In Situ Hybridization market-level with all segments.
  • PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
  • Product mapping available as excel consisting of key products of all the major players.

The global In Situ Hybridization market report would provide approximately 61 tables, 58 figures, and 195 Pages.

Target Audience 2023

  • Manufacturers/ Buyers
  • Industry Investors/Investment Bankers
  • Research Professionals
  • Emerging Companies

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1. Snippet by Type
  • 3.2. Snippet by Application
  • 3.3. Snippet by End User
  • 3.4. Snippet by Region

4. Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Increasing incidence of Cancer cases
      • 4.1.1.2. Awareness about companion diagnostics
      • 4.1.1.3. XX
    • 4.1.2. Restraints
      • 4.1.2.1. Lack of trained personnel will hamper the market
      • 4.1.2.2. XX
    • 4.1.3. Opportunity
      • 4.1.3.1. XX
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Forces Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Pricing Analysis
  • 5.4. Regulatory Analysis
  • 5.5. Unmet needs
  • 5.6. Pipe line analysis

6. COVID-19 Analysis

  • 6.1. Analysis of COVID-19
    • 6.1.1. Before COVID-19 Scenario
    • 6.1.2. Present COVID-19 Scenario
    • 6.1.3. PostCOVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid COVID-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During the Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. By Product

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 7.1.2. Market Attractiveness Index, By Type
  • 7.2. Consumables*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 7.3. Instruments
  • 7.4. Software

8. By Technology

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 8.1.2. Market Attractiveness Index, By Application
  • 8.2. FISH*
    • 8.2.1. DNA FISH
    • 8.2.2. RNA FISH
    • 8.2.3. PNA FISH
    • 8.2.4. Introduction
    • 8.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 8.3. CISH

9. By Application

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), ByApplication
    • 9.1.2. Market Attractiveness Index, By Application
  • 9.2. Cancer Diagnostics*
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 9.3. Cytology
  • 9.4. Infectious Disease Diagnostics
  • 9.5. Neuroscience
  • 9.6. Immunology

10. By End User

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 10.1.2. Market Attractiveness Index, By Application
  • 10.2. Hospitals & Diagnostic Laboratories*
    • 10.2.1. Introduction
    • 10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 10.3. Academic & Research Institutes
  • 10.4. Pharmaceutical & Biotechnology Companies
  • 10.5. Contract research organizations

11. By Region

  • 11.1. Introduction
    • 11.1.1. Market Size Analysis andY-o-Y Growth Analysis (%), By Region
    • 11.1.2. Market Attractiveness Index, By Region
  • 11.2. North America
    • 11.2.1. Introduction
    • 11.2.2. Key Region-Specific Dynamics
    • 11.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
    • 11.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
    • 11.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 11.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 11.2.7. Market Size Analysis andY-o-Y Growth Analysis (%), By Country
      • 11.2.7.1. U.S.
      • 11.2.7.2. Canada
      • 11.2.7.3. Mexico
  • 11.3. Europe
    • 11.3.1. Introduction
    • 11.3.2. Key Region-Specific Dynamics
    • 11.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
    • 11.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
    • 11.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 11.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 11.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.3.7.1. Germany
      • 11.3.7.2. UK
      • 11.3.7.3. France
      • 11.3.7.4. Italy
      • 11.3.7.5. Russia
      • 11.3.7.6. Rest of Europe
  • 11.4. South America
    • 11.4.1. Introduction
    • 11.4.2. Key Region-Specific Dynamics
    • 11.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
    • 11.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
    • 11.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 11.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 11.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.4.7.1. Brazil
      • 11.4.7.2. Argentina
      • 11.4.7.3. Rest of South America
  • 11.5. Asia-Pacific
    • 11.5.1. Introduction
    • 11.5.2. Key Region-Specific Dynamics
    • 11.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
    • 11.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
    • 11.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 11.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 11.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.5.7.1. China
      • 11.5.7.2. India
      • 11.5.7.3. Japan
      • 11.5.7.4. Australia
      • 11.5.7.5. Rest of Asia-Pacific
  • 11.6. Middle East and Africa
    • 11.6.1. Introduction
    • 11.6.2. Key Region-Specific Dynamics
    • 11.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
    • 11.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
    • 11.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 11.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User

12. Competitive Landscape

  • 12.1. Competitive Scenario
  • 12.2. Market Positioning/Share Analysis
  • 12.3. Mergers and Acquisitions Analysis

13. Company Profiles

  • 13.1. Abbott Laboratories*
    • 13.1.1. Company Overview
    • 13.1.2. Product Portfolio and Description
    • 13.1.3. Financial Overview
    • 13.1.4. Key Developments
  • 13.2. F. Hoffmann-La Roche Ag.
  • 13.3. Becton, Dickinson And Company
  • 13.4. Agilent Technologies, Inc.
  • 13.5. Thermo Fisher Scientific
  • 13.6. Bio-Rad Laboratories, Inc.
  • 13.7. Bio-Techne Corporation
  • 13.8. Creative Bioarray
  • 13.9. Biocat Gmbh
  • 13.10. Zytovision.

LIST NOT EXHAUSTIVE

14. Appendix

  • 14.1. About Us and Services
  • 14.2. Contact Us